The ALDH1A1 Knockout HAP1 Polyclonal Cells product provides a polyclonal population of HAP1 cells harboring a CRISPR/Cas9-mediated disruption of the endogenous ALDH1A1 locus. This gene-edited cell pool is designed to establish a loss-of-function model free from potential clonal biases, enabling robust functional interrogation of aldehyde dehydrogenase 1A1 activity in a near-haploid human background. As a heterogeneous knockout population, the product circumvents artifacts arising from single-cell adaptation and facilitates studies requiring population-level readouts, such as chemical screening, dose-response assays, and pooled functional genomics workflows. The knockout is achieved through CRISPR/Cas9-mediated genome editing, resulting in targeted gene disruption without predetermined clonal genotypes, making it ideal for researchers who demand reproducible and physiologically relevant model systems.
The host cell line, HAP1, is a male-derived chronic myeloid leukemia (CML) line exhibiting a near-haploid karyotype, with the exception of disomy 8, and an adherent, fibroblastoid morphology. Originally derived from a CML patient, HAP1 cells retain a largely haploid genome, which simplifies genetic analysis by eliminating the confounding effects of allelic variation and enabling unambiguous assignment of phenotypes to single-gene perturbations. This genetic simplicity, combined with a stable proliferation rate and compatibility with standard molecular and cell biology techniques, positions HAP1 as a powerful chassis for studying gene function, epistasis, and drug action. The cell line’s haploid nature is particularly advantageous for knockout studies, as a single mutational event is sufficient to produce a null phenotype, thus accelerating the generation of isogenic models.
ALDH1A1 encodes a cytosolic aldehyde dehydrogenase that catalyzes the NAD+-dependent oxidation of retinaldehyde to all-trans retinoic acid, a potent morphogen and transcriptional regulator. The enzyme functions as a homotetramer, and its activity is positively regulated by nuclear factor erythroid 2-related factor 2 (NRF2), the aryl hydrocarbon receptor (AhR), and peroxisome proliferator-activated receptor gamma (PPAR??), in addition to retinoic acid itself, establishing a feedback circuit. The major downstream consequence of ALDH1A1 activity is the generation of retinoic acid, which serves as a ligand for retinoic acid receptors (RARs) and retinoid X receptors (RXRs), thereby directly activating the transcription of retinoic acid-responsive genes, most notably the Hox gene clusters. Consequently, ALDH1A1 integrates signals from xenobiotic and metabolic sensors to modulate developmental and differentiation pathways, while simultaneously contributing to cellular detoxification by oxidizing a broad range of reactive aldehydes, including those derived from ethanol metabolism.
In the HAP1 context, knockout of ALDH1A1 eliminates the primary enzymatic route for converting retinaldehyde to retinoic acid, thereby abrogating autocrine and paracrine retinoic acid signaling. Given HAP1’s haploid genome, this disruption simulates a complete loss of retinoic acid biosynthesis, permitting the dissection of retinoic acid-dependent processes such as differentiation, proliferation control, and oxidative stress responses without interference from a wild-type allele. Because ALDH1A1 is often used as a functional marker of cancer stem cells in malignancies ranging from lung cancer to leukemia, the HAP1 knockout population serves as a surrogate to investigate the molecular consequences of ALDH1A1 deficiency in a malignant background. Additionally, the model allows direct assessment of how ALDH1A1 activity impacts the cellular response to chemotherapeutics and the detoxification of endogenous aldehydes, linking the gene to drug resistance and metabolic vulnerabilities.
The ALDH1A1 Knockout HAP1 Polyclonal Cells are suited for a broad spectrum of experimental applications. Researchers can employ ALDEFLUOR-based flow cytometry or enzymatic activity assays to confirm the loss of aldehyde dehydrogenase function, while RT-qPCR and Western blotting enable quantification of transcript and protein levels, respectively. RNA-seq experiments can map global transcriptomic changes following retinoic acid withdrawal or oxidative challenge, and retinoic acid reporter assays (e.g., RARE-luciferase) directly measure signaling output. The model is particularly valuable for chemical screens aiming to identify ALDH1A1 inhibitors or synthetic lethal partners, as well as for studies of alcohol metabolism and cancer stem cell biology. For further technical specifications or to request a quote, please contact Ascent Research.
